The addition of carboplatin to anthra-free regimens and double HER2 blockade has been correlated with a numerical increase in pCR rates [21–23] and event-free survival (EFS), at the expense of an increased incidence of thrombocytopenia of G > 2 (13%) [24]. Here, ERBB2 is linked to Thrombocytopenia.